PDCD1 and neoplasm: As a result, Iacs-miR-30C/Anti-PD-1 combo therapy led to dramatically increased TGI value (94.3% TGI) as compared to anti-PD-1 therapy (37.5% TGI) or Iacs-miR-30C therapy (62.7% TGI) (Fig. 6G and H), in line with the results of the tumor photos (Fig. 6I) and weights (Fig. 6J).